KNSA240719C20000
- 1.92
- +0.22+12.94%
Kiniksa Pharmaceuticals International Newsroom
Kiniksa Pharmaceuticals to Report Second Quarter 2024 Financial Results on July 23, 2024
LONDON, July 16, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) announced today that it will host a conference call and live webcast on Tuesday, July 23, 2024 at 8:30 a.m. Eastern
The 13% Return This Week Takes Kiniksa Pharmaceuticals International's (NASDAQ:KNSA) Shareholders Three-year Gains to 60%
Express News | Kiniksa Pharmaceuticals Ltd - Expects to Remain Cash Flow Positive Annually
Express News | Kiniksa Pharmaceuticals Ltd - Abiprubart Trial in Sjögren's Disease Fully Funded
Express News | Kiniksa Pharmaceuticals Commences Enrollment in Abiprubart Phase 2B Clinical Trial in Sjögren’s Disease
Kiniksa Pharmaceuticals Files $400 Million Mixed Shelf
Kiniksa Pharmaceuticals (KNSA) on Friday filed a registration statement for the potential offering of up to $400 million worth of securities from time to time. The filing covers the potential sale of
Express News | Kiniksa Pharmaceuticals Ltd Files for Mixed Shelf of up to $400 Mln - SEC Filing
Sector Update: Health Care Stocks Mixed Pre-Bell Wednesday
Health care stocks were mixed pre-bell Wednesday, with the iShares Biotechnology ETF (IBB) down 0.1% and the Health Care Select Sector SPDR Fund (XLV) up 0.5% recently. Savara (SVRA) rose past 17% aft
Express News | Kiniksa Pharmaceuticals - Samsung to Perform Tech. Transfer, Process Performance Qualification, Manufacturing & Supply Services for Supply of Arcalyst
Express News | Kiniksa Pharmaceuticals Ltd - Unit Entered Master Services Agreement and Product Specific Agreement With Samsung Biologics Co., Ltd.
Small-cap, Buy-rated Stocks With Positive Estimate Revision Factors - BofA
Kiniksa Pharmaceuticals (NASDAQ:KNSA) Pulls Back 3.9% This Week, but Still Delivers Shareholders Decent 6.4% CAGR Over 5 Years
The main point of investing for the long term is to make money. Better yet, you'd like to see the share price move up more than the market average. But Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) ha
Kiniksa Pharmaceuticals Sponsors American Heart Association's Addressing Recurrent Pericarditis Initiative
PDF Version – Initiative aimed at improving access and outcomes for patients with recurrent pericarditis –– American Heart Association to work with champions at 15 healthcare sites to implement i
Express News | Kiniksa Pharmaceuticals Ltd - Supreme Court of Bermuda Issued an Order Sanctioning Scheme of Arrangement Between Company and Its Shareholders
Express News | Kiniksa Pharmaceuticals Ltd - Expects Redomiciliation to Take Effect on or Around June 27, 2024
Kiniksa Pharmaceuticals to Present at Goldman Sachs 45th Annual Global Healthcare Conference
PDF Version HAMILTON, Bermuda, June 04, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the Goldman
Sector Spotlight: Orphan Drug Developers With Significant Upside
Market Underestimates Kiniksa Pharmaceuticals' Abiprubart Potential Despite Positive Industry Indicators
Kiniksa Pharmaceuticals to Present at Bank of America Securities 2024 Health Care Conference
PDF Version HAMILTON, Bermuda, May 07, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the Bank of A
Kiniksa Pharmaceuticals (KNSA.US) was covered for the first time by Wells Fargo, giving it an increase rating, with a target price of $34.00.
Kiniksa Pharmaceuticals (KNSA.US) was covered for the first time by Wells Fargo, giving it an increase rating, with a target price of $34.00.